Literature DB >> 7860229

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study.

J O Atiba1, S J Green, H E Hynes, C K Osborne, T P Miller, M Davidner.   

Abstract

The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m2 to 12.0 mg/m2) and cis-platinum (100 mg/m2) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7860229     DOI: 10.1007/bf00874442

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  9 in total

1.  Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study.

Authors:  H T Mouridsen; C Rose; M A Nooy; A T van Oosterom
Journal:  Cancer Treat Rev       Date:  1983-12       Impact factor: 12.111

2.  Clinical safety and tolerance of mitoxantrone (Novantrone).

Authors:  R J Crossley
Journal:  Cancer Treat Rev       Date:  1983-12       Impact factor: 12.111

Review 3.  Therapeutic activity of mitoxantrone and ametantrone against murine tumors.

Authors:  F M Schabel; T H Corbett; D P Griswold; W R Laster; M W Trader
Journal:  Cancer Treat Rev       Date:  1983-12       Impact factor: 12.111

4.  Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial.

Authors:  J A Neidhart; D Gochnour; R W Roach; J A Steinberg; D Young
Journal:  Cancer Treat Rev       Date:  1983-12       Impact factor: 12.111

5.  Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules.

Authors:  A A Forastiere; T B Hakes; J T Wittes; R E Wittes
Journal:  Am J Clin Oncol       Date:  1982-06       Impact factor: 2.339

Review 6.  Cisplatin in the management of breast cancer.

Authors:  G W Sledge; B J Roth
Journal:  Semin Oncol       Date:  1989-08       Impact factor: 4.929

7.  Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer.

Authors:  I E Smith; R Stuart-Harris; N Pavlidis; T Bozek
Journal:  Cancer Treat Rev       Date:  1983-12       Impact factor: 12.111

8.  Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer.

Authors:  K Kolarić; A Roth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.

Authors:  J D Cowan; J Neidhart; S McClure; C A Coltman; C Gumbart; S Martino; L F Hutchins; R L Stephens; C B Vaughan; C K Osborne
Journal:  J Natl Cancer Inst       Date:  1991-08-07       Impact factor: 13.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.